This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

​Valeant sells iNova Pharmaceuticals to PEP, Carlyle for $930 million, subject to approvals

( June 9, 2017, 06:05 GMT | Official Statement) -- MLex Summary: NYSE-listed Valeant Pharmaceuticals International has agreed to sell its Australia-based iNova Pharmaceuticals business to a company jointly owned by funds advised and managed by Australasian firm Pacific Equity Partners and The Carlyle Group for $930 million in cash. The transaction is expected to close in the second half of 2017, subject to regulatory approvals.The company's full statement follows: ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login